ImmunoCellular Therapeutics (IMUC -13.8%) slides after pricing its secondary offering of 10M...

|About: ImmunoCellular Therapeutics... (IMUC)|By:, SA News Editor

ImmunoCellular Therapeutics (IMUC -13.8%) slides after pricing its secondary offering of 10M shares at $2.10, a 13% discount to yesterday's close. The company also is offering warrants to purchase as many as 4.5M additional shares. It plans to use the proceeds for the ongoing clinical development of its brain cancer treatment and lead pipeline product, ICT-107, as well as for general corporate purposes. The company had 40.6 million shares outstanding as of August.